pegcetacoplan
Apellis therapy outflanks Alexion’s Soliris in head-to-head paroxysmal nocturnal haemoglobinuria
January 8, 2020Research and Development Alexion, Appelis, pegcetacoplan, pharma, soliris
Apellis Pharmaceuticals has revealed new Phase 3 demonstrating that its targeted C3 inhibitor pegcetacoplan met its primary endpoint and outclassed …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
